STRIDES PHARMA SCI LTDViés de alta
Accumulate, Hold for Long term
Excellent Opportunity to buy the stock. Strides revenues in Q4FY21 grew by 47% YoY to Rs.908 cr during the quarter with sales growth in the regulated markets and emerging markets.
I have entered around the 770 mark as Investment and plan to hold for long term
Chart study, not a call
I have entered around the 770 mark as Investment and plan to hold for long term
Chart study, not a call
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.